MCM
NVO

MAI Capital Management’s Novo Nordisk NVO Stock Holding History

MAI Capital Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.54M Buy
52,885
+8,252
+18% +$355K 0.01% 641
2026
Q1 		$1.64M Buy
44,633
+1,937
+5% +$91.8K 0.01% 630
2025
Q4 		$2.17M Sell
42,696
-564
-1% -$28.8K 0.01% 551
2025
Q3 		$2.4M Sell
43,260
-4,251
-9% -$249K 0.02% 498
2025
Q2 		$3.28M Buy
47,511
+2,144
+5% +$146K 0.02% 402
2025
Q1 		$3.15M Sell
45,367
-310
-0.7% -$25.6K 0.02% 394
2024
Q4 		$3.93M Buy
45,677
+16,719
+58% +$1.81M 0.03% 361
2024
Q3 		$3.45M Sell
28,958
-19,709
-40% -$2.63M 0.03% 307
2024
Q2 		$6.95M Sell
48,667
-1,654
-3% -$219K 0.07% 213
2024
Q1 		$6.46M Buy
50,321
+16,975
+51% +$2.02M 0.07% 216
2023
Q4 		$3.45M Buy
33,346
+2,527
+8% +$250K 0.05% 245
2023
Q3 		$2.8M Sell
30,819
-97
-0.3% -$8.54K 0.04% 252
2023
Q2 		$2.5M Buy
30,916
+9,886
+47% +$808K 0.04% 259
2023
Q1 		$1.67M Buy
21,030
+1,704
+9% +$121K 0.03% 324
2022
Q4 		$1.31M Buy
19,326
+1,136
+6% +$66.6K 0.02% 361
2022
Q3 		$906K Sell
18,190
-11,878
-40% -$636K 0.02% 395
2022
Q2 		$1.68M Buy
30,068
+2,962
+11% +$164K 0.03% 290
2022
Q1 		$1.5M Sell
27,106
-658
-2% -$33.8K 0.03% 319
2021
Q4 		$1.55M Sell
27,764
-3,694
-12% -$200K 0.03% 333
2021
Q3 		$1.51M Buy
31,458
+638
+2% +$30.8K 0.03% 290
2021
Q2 		$1.29M Sell
30,820
-112
-0.4% -$4.34K 0.03% 309
2021
Q1 		$1.04M Buy
30,932
+6,072
+24% +$216K 0.02% 327
2020
Q4 		$868K Sell
24,860
-262
-1% -$9.06K 0.02% 351
2020
Q3 		$872K Buy
25,122
+1,630
+7% +$54.3K 0.03% 305
2020
Q2 		$769K Sell
23,492
-1,180
-5% -$37.7K 0.02% 331
2020
Q1 		$743K Sell
24,672
-3,600
-13% -$107K 0.03% 304
2019
Q4 		$818K Buy
28,272
+18,916
+202% +$524K 0.03% 329
2019
Q3 		$242K Hold
9,356
– – 0.01% 461
2019
Q2 		$239K Buy
+9,356
New +$231K 0.01% 460

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

MAI Capital Management's NVO Position: Q2 2026 in Review

MAI Capital Management increased its Novo Nordisk (NVO) stake by 18% in Q2 2026, buying an estimated $355K and bringing the position to 52,885 shares worth $2.54M. The position accounts for 0.01% of the portfolio, ranked #641.

MAI Capital Management first reported a position in NVO in Q2 2019 and has held it in 29 quarters since. The position peaked at $6.95M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • MAI Capital Management held 52,885 shares of Novo Nordisk worth $2.54M as of Q2 2026.
  • MAI Capital Management bought 8,252 Novo Nordisk shares in Q2 2026, an estimated $355K.
  • Novo Nordisk made up 0.01% of MAI Capital Management's portfolio in Q2 2026, its #641 holding.
  • MAI Capital Management first reported a position in Novo Nordisk in Q2 2019 and has held it in 29 quarters since.
  • MAI Capital Management's Novo Nordisk position peaked at $6.95M in Q2 2024.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.